OPM Biosciences

OPM Biosciences, formally Shanghai OPM Biosciences Co., Ltd., is a publicly-traded biotechnology company operating as an integrated solutions provider for the biopharmaceutical industry. The company was established in Shanghai, China, in 2013 by Dr. Zhihua Xiao, who currently serves as Chairman and CEO. Dr. Xiao's career, with over 25 years in mammalian cell culture and therapeutic drug development, laid the groundwork for OPM's focus. He identified a significant market gap in China for domestically produced, high-quality cell culture media, a critical component in biopharmaceutical manufacturing that was predominantly import-reliant.

The company operates on a dual-pillar business model, providing both cell culture media (CCM) products and end-to-end Contract Development and Manufacturing Organization (CDMO) services. This synergistic approach allows OPM to support clients from the initial DNA and cell line development stages through to Investigational New Drug (IND) and Biologics License Application (BLA) filings. The CDMO services not only generate revenue but also drive the adoption of its proprietary culture media. OPM serves a global clientele of over 1,000 pharmaceutical companies, biotech firms, and research institutions, aiming to reduce the total cost of new drug development. Revenue is generated through the sale of its catalog and customized media products, as well as fee-for-service contracts for its comprehensive CDMO offerings.

OPM's core product is its extensive line of cell culture media, which are essentially nutrient broths for growing cells used in the production of antibodies, vaccines, and cell and gene therapies. Its service portfolio is extensive, covering antibody discovery, stable cell line construction, process development and optimization, and pilot-scale production in state-of-the-art facilities with single-use bioreactors. A key achievement was becoming China's first publicly listed provider of cell culture solutions, listing on the Shanghai Stock Exchange (SHA: 688293). The company has since expanded internationally, establishing laboratories and offices in the USA to better serve North American and European markets.

Keywords: cell culture media, CDMO services, biopharmaceutical, contract development and manufacturing, biologics, antibody discovery, cell line development, process development, biomanufacturing, GMP manufacturing, upstream processing, downstream processing, CHO platform, biologics manufacturing, drug development, therapeutic antibodies, vaccine production, cell therapy, gene therapy, single-use bioreactors